Terms: = Colorectal cancer AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Treatment
1935 results:
1. Apoptotic effect of 5-fluorouracil-doxorubicin combination on colorectal cancer cell monolayers and spheroids.
Bilgin S
Mol Biol Rep; 2024 May; 51(1):603. PubMed ID: 38698270
[TBL] [Abstract] [Full Text] [Related]
2. The Relationship of Microsatellite Instability with BRAF and p53 Mutations and Histopathological Parameters in colorectal Adenocarcinoma.
Gündoğar Ö; Bektaş S; Yıldırım E; Gönüllü D
Ann Ital Chir; 2024; 95(2):181-191. PubMed ID: 38684491
[TBL] [Abstract] [Full Text] [Related]
3. Exploring the Key Signaling Pathways and ncRNAs in colorectal cancer.
Lee YJ; Kim WR; Park EG; Lee DH; Kim JM; Shin HJ; Jeong HS; Roh HY; Kim HS
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674135
[TBL] [Abstract] [Full Text] [Related]
4. Clinical impact of panel gene sequencing on therapy of advanced cancers of the digestive system: a retrospective, single center study.
Dreikhausen L; Klupsch A; Wiest I; Xiao Q; Schulte N; Betge J; Boch T; Brochhausen C; Gaiser T; Hofheinz RD; Ebert M; Zhan T
BMC Cancer; 2024 Apr; 24(1):526. PubMed ID: 38664720
[TBL] [Abstract] [Full Text] [Related]
5. Proteasome activation is critical for cell death induced by inhibitors of polo-like kinase 1 (PLK1) in multiple cancers.
Wang Y; Wang G; Xiang W; Liu X; Jiang M; Hu J
Eur J Pharmacol; 2024 Jun; 972():176558. PubMed ID: 38614382
[TBL] [Abstract] [Full Text] [Related]
6. Promising Anticancer Prodrugs Based on Pt(IV) Complexes with Bis-organosilane Ligands in Axial Positions.
Navas F; Chocarro-Calvo A; Iglesias-Hernández P; Fernández-García P; Morales V; García-Martínez JM; Sanz R; De la Vieja A; García-Jiménez C; García-Muñoz RA
J Med Chem; 2024 Apr; 67(8):6410-6424. PubMed ID: 38592014
[TBL] [Abstract] [Full Text] [Related]
7. Biogenic Zinc Oxide Nanoparticles synthesized from
Berehu HM; Patnaik S
Nanotheranostics; 2024; 8(3):312-329. PubMed ID: 38577319
[TBL] [Abstract] [Full Text] [Related]
8. Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer.
D'Agostino E; Mastrodomenico L; Ponzoni O; Baldessari C; Piombino C; Pipitone S; Giuseppa Vitale M; Sabbatini R; Dominici M; Toss A
Cancer Treat Rev; 2024 May; 126():102723. PubMed ID: 38555857
[TBL] [Abstract] [Full Text] [Related]
9. Prediction of potential mechanisms of rhubarb therapy for colorectal cancer based on network pharmacological analysis and molecular docking.
Yang F; Li X; Zhang Y; Ren Y; Zhang J; Xiao K
Medicine (Baltimore); 2024 Mar; 103(12):e37477. PubMed ID: 38518016
[TBL] [Abstract] [Full Text] [Related]
10. CircHAS2 activates CCNE2 to promote cell proliferation and sensitizes the response of colorectal cancer to anlotinib.
Li H; Feng H; Zhang T; Wu J; Shen X; Xu S; Xu L; Wang S; Zhang Y; Jia W; Ji X; Cheng X; Zhao R
Mol Cancer; 2024 Mar; 23(1):59. PubMed ID: 38515149
[TBL] [Abstract] [Full Text] [Related]
11. Epigenetic MLH1 silencing concurs with mismatch repair deficiency in sporadic, naturally occurring colorectal cancer in rhesus macaques.
Deycmar S; Johnson BJ; Ray K; Schaaf GW; Ryan DP; Cullin C; Dozier BL; Ferguson B; Bimber BN; Olson JD; Caudell DL; Whitlow CT; Solingapuram Sai KK; Romero EC; Villinger FJ; Burgos AG; Ainsworth HC; Miller LD; Hawkins GA; Chou JW; Gomes B; Hettich M; Ceppi M; Charo J; Cline JM
J Transl Med; 2024 Mar; 22(1):292. PubMed ID: 38504345
[TBL] [Abstract] [Full Text] [Related]
12. Dynamic ctDNA-based analysis of drug-resistant gene alterations at RAS/BRAF wild-type metastatic colorectal cancer patients after cetuximab plus chemotherapy as the first-line treatment.
Zhou YW; Zhao X; Ni L; Cao P; Leng WB; Zhu Q; Gou HF; Zhang J; Li XF; Qiu M
Int Immunopharmacol; 2024 Apr; 131():111887. PubMed ID: 38503018
[TBL] [Abstract] [Full Text] [Related]
13. Differential genetic mutations and immune cell infiltration in high- and low-risk STAD: Implications for prognosis and immunotherapy efficacy.
Deng YY; Sun Y; Wu SJ; Zhang TY; Yang J; Liu K
J Cell Mol Med; 2024 Apr; 28(7):e18174. PubMed ID: 38494839
[TBL] [Abstract] [Full Text] [Related]
14. Evaluating the role of wound-healing genes in conjunction with stool routine and serum tumor markers for colorectal cancer diagnosis and prognostic implications.
Yu K; Fang X
Int Wound J; 2024 Mar; 21(3):e14768. PubMed ID: 38446012
[TBL] [Abstract] [Full Text] [Related]
15. Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer.
Liu H; Zhou D; Liu D; Xu X; Zhang K; Hu R; Xiong P; Wang C; Zeng X; Wang L; Zhang S
Cell Death Dis; 2024 Mar; 15(3):187. PubMed ID: 38443386
[TBL] [Abstract] [Full Text] [Related]
16. Targeting mitochondrial bioenergetics by combination treatment with imatinib and dichloroacetate in human erythroleukemic K‑562 and colorectal HCT‑116 cancer cells.
Kakafika MG; Lyta AA; Gavriilidis GI; Tsiftsoglou SA; Miliotou AN; Pappas IS; Vizirianakis IS; Papadopoulou LC; Tsiftsoglou AS
Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38426621
[TBL] [Abstract] [Full Text] [Related]
17. Morindone as a potential therapeutic compound targeting tp53 and KRAS mutations in colorectal cancer cells.
Chee CW; Mohd Hashim N; Nor Rashid N
Chem Biol Interact; 2024 Apr; 392():110928. PubMed ID: 38423379
[TBL] [Abstract] [Full Text] [Related]
18. Tumor location matters, next generation sequencing mutation profiling of left-sided, rectal, and right-sided colorectal tumors in 552 patients.
Ciepiela I; Szczepaniak M; Ciepiela P; Hińcza-Nowak K; Kopczyński J; Macek P; Kubicka K; Chrapek M; Tyka M; Góźdź S; Kowalik A
Sci Rep; 2024 Feb; 14(1):4619. PubMed ID: 38409377
[TBL] [Abstract] [Full Text] [Related]
19. A synergistic two-drug therapy specifically targets a DNA repair dysregulation that occurs in p53-deficient colorectal and pancreatic cancers.
Alruwaili MM; Zonneville J; Naranjo MN; Serio H; Melendy T; Straubinger RM; Gillard B; Foster BA; Rajan P; Attwood K; Chatley S; Iyer R; Fountzilas C; Bakin AV
Cell Rep Med; 2024 Mar; 5(3):101434. PubMed ID: 38387463
[TBL] [Abstract] [Full Text] [Related]
20. Induction of G0/G1 phase cell cycle arrest and apoptosis by thymol through ROS generation and caspase-9/-3 activation in breast and colorectal cancer cell lines.
Anvarbatcha R; Kunnathodi F; Islam M
J Cancer Res Ther; 2023 Oct; 19(7):1915-1924. PubMed ID: 38376297
[TBL] [Abstract] [Full Text] [Related]
[Next]
